KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Investing Activities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Cash from Investing Activities for 7 consecutive years, with -$2.2 million as the latest value for Q3 2023.

  • On a quarterly basis, Cash from Investing Activities fell 180.74% to -$2.2 million in Q3 2023 year-over-year; TTM through Sep 2023 was $50.6 million, a 121.73% increase, with the full-year FY2025 number at -$24.8 million, down 706.32% from a year prior.
  • Cash from Investing Activities was -$2.2 million for Q3 2023 at Twist Bioscience, down from $18.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $104.6 million in Q2 2021 to a low of -$226.6 million in Q4 2021.
  • A 5-year average of -$9.5 million and a median of -$1.2 million in 2019 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 7875.48% in 2020, then soared 409.61% in 2023.
  • Twist Bioscience's Cash from Investing Activities stood at $12.4 million in 2019, then crashed by 470.18% to -$45.9 million in 2020, then tumbled by 393.42% to -$226.6 million in 2021, then skyrocketed by 96.92% to -$7.0 million in 2022, then surged by 67.77% to -$2.2 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Cash from Investing Activities are -$2.2 million (Q3 2023), $18.7 million (Q2 2023), and $41.2 million (Q1 2023).